TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Guide

Compounded Tirzepatide Online: Legal, Safety and Cost Guide

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

This guide explains the practical and regulatory landscape behind the question in the title, separates what the evidence establishes from what it does not, and gives you a verification checklist you can use on any provider. It is educational and does not recommend a medication, a dose or a provider for you.

Answer last reviewed:
How tirzepatide compounding became a regulatory question
2022Tirzepatide added to the F2024-10FDA declared the tirzepati2025-02FDA declared the semagluti2025-09-16FDA issued 55+ warning let2026-02-09Novo Nordisk sued Hims & H2026-03-03FDA released 30 further wa2026-03-09Hims & Hers settled with N2026-04-30FDA proposed excluding tir2026-05-01Formal notice published at2026-06-26Comment period extended to2026-07-30Comment period closes
Show this figure as a table
Data table
DateEvent
2022Tirzepatide added to the F
2024-10FDA declared the tirzepati
2025-02FDA declared the semagluti
2025-09-16FDA issued 55+ warning let
2026-02-09Novo Nordisk sued Hims & H
2026-03-03FDA released 30 further wa
2026-03-09Hims & Hers settled with N
2026-04-30FDA proposed excluding tir
2026-05-01Formal notice published at
2026-06-26Comment period extended to
2026-07-30Comment period closes
Every event above links to the agency's own document, not to coverage of it.
What each step actually changedPrimary sources · captured 2026-07-26
What each step actually changed
DateWhat happenedEffect on compounded access
2022Tirzepatide added to the FDA drug shortage listA shortage listing is what permitted compounders to make copies of the approved product.
2024-10FDA declared the tirzepatide shortage resolvedRemoving the shortage listing removed one of the two legal pathways for compounding tirzepatide.
2025-02FDA declared the semaglutide shortage resolvedThe same pathway closed for semaglutide four months later.
2025-09-16FDA issued 55+ warning letters to online GLP-1 sellersLetters cited misleading direct-to-consumer advertising of compounded GLP-1 products.
2026-02-09Novo Nordisk sued Hims & Hers over compounded semaglutidePatent infringement claim following the launch of a low-cost compounded oral product.
2026-03-03FDA released 30 further warning letters to telehealth firmsTargeting claims that compounded GLP-1s are equivalent to the branded products.
2026-03-09Hims & Hers settled with Novo Nordisk and pivoted to branded supplyHims agreed to offer branded semaglutide and cease most compounded GLP-1 marketing. The largest compounded seller in the category left it. This changes who is actually in the compounded market.
2026-04-30FDA proposed excluding tirzepatide from the 503B bulks listThe agency found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. This proposal targets the second and last remaining pathway.
2026-05-01Formal notice published at 91 Fed. Reg. 23431Docket 2026-08552 sets out the agency's substance-by-substance reasoning.
2026-06-26Comment period extended to 30 July 2026FDA granted an extension after a request for more time to respond. Comments inform, but do not bind, the final determination.
2026-07-30Comment period closesAfter this date the agency considers submissions before making a final determination. No final determination had published as of 24 July 2026.
A proposal is not a final rule. Nothing here says compounded tirzepatide is unlawful today.
Approved product against compounded preparation
Approved product against compounded preparation
AttributeFDA-approved tirzepatide (Zepbound, Mounjaro)Compounded tirzepatide
Regulatory statusApproved finished drug productNot an FDA-approved product
Generic equivalentNo generic tirzepatide existsNot a generic and not therapeutically equivalent
Manufacturing standardManufactured under CGMPDepends on the compounder's registration class
Clinical trial evidenceStudied in the registration trialsTrials studied the approved product, not this preparation
LabellingFDA-approved labellingSupplied by the compounder
PresentationManufacturer's pens or vialsVaries; multi-dose vials add a measuring step
Price read on the seller’s own page——

A dash means no figure held. How we grade evidence.

No provider may describe a compounded preparation as FDA-approved or as generic Zepbound. Both statements are false, and both are common.
503A pharmacy against 503B outsourcing facilityStatutory distinction · pending legal review
503A pharmacy against 503B outsourcing facility
Requirement503A compounding pharmacy503B outsourcing facility
Compounds pursuant toA prescription for an identified individual patientMay compound without patient-specific prescriptions
FDA registrationNot registered as an outsourcing facilityRegisters with FDA
CGMP requirementsNot required to meet CGMPMust comply with CGMP — though registration alone is not evidence of compliance
Primary oversightState board of pharmacyFDA, on a risk-based inspection schedule
Adverse-event reportingNot required under 503ARequired to report adverse events to FDA
Product approval statusNot an FDA-approved productNot an FDA-approved product
What registration establishesNot applicableFDA received the required information, nothing more Verified
Neither route produces an FDA-approved medicine. Registration and inspection are not approval, and no accreditation changes that.
Verify any provider in ten minutes
1Find the full priceEvery required fee, not the headline figure. Screenshot it.2Identify the pharmacyAsk which pharmacy or outsourcing facility fills the prescription.3Check its registrationState board licence lookup, and FDA registration if it claims 503B.4Confirm the prescriberState board of medicine licence lookup, by name.5Read the cancellation termsBefore ordering, not after.6Ask what happens at higher dosesGet the surcharge in writing.
Show this figure as a table
Data table
StepStageWhat happens
1Find the full priceEvery required fee, not the headline figure. Screenshot it.
2Identify the pharmacyAsk which pharmacy or outsourcing facility fills the prescription.
3Check its registrationState board licence lookup, and FDA registration if it claims 503B.
4Confirm the prescriberState board of medicine licence lookup, by name.
5Read the cancellation termsBefore ordering, not after.
6Ask what happens at higher dosesGet the surcharge in writing.

What the rules actually say

The primary sources, briefly:

  • Compounding is legal under conditions. Section 503A covers state-licensed pharmacies compounding for identified patients against a valid prescription. Section 503B covers FDA-registered outsourcing facilities. A compounded drug skips FDA approval only if those conditions are met.
  • It is not approved. FDA's page on unapproved GLP-1s (current as of October 1, 2026) says plainly that "compounded drugs are not FDA approved."
  • The shortage route is closed. FDA declared the tirzepatide shortage resolved in October 2024.
  • The 503B route is under review. On April 30, 2026, FDA proposed not to place tirzepatide on the 503B bulks list (91 FR 23431). Comments closed July 30, 2026. A Federal Register search on November 9, 2026 found no final decision.

Prohibited: dispensing without a valid prescription, and 503A pharmacies routinely making copies of an approved product. Calling the product FDA-approved or generic is simply false.

Undocumented: how many people use compounded tirzepatide, which pharmacy supplies which program unless the program says, and how FDA will rule.

What the evidence supports

The evidence for tirzepatide comes from trials of Lilly's approved product. In SURMOUNT-1, adults with obesity and without diabetes had a mean weight change of −20.9% on 15 mg over 72 weeks, against −3.1% on placebo (treatment-regimen estimand). In SURMOUNT-5, tirzepatide at the maximum tolerated dose produced −20.2% against −13.7% for semaglutide over 72 weeks.

These trials show what tirzepatide can do when it is manufactured to the approved specification, dosed as the protocol set out, and followed up.

What carries over to a compounded preparation: the pharmacology. A preparation made with tirzepatide at the strength on its label acts on the same receptors.

What does not carry over automatically: the size of the effect, the side-effect profile and the safety record. Those depend on the vial holding the stated strength, on the preparation being sterile, and on the dose being measured correctly. The trials tested none of these for a compounded product.

What the evidence does not establish

  • Effectiveness. The trial publications and FDA documents we track contain no randomised trial of compounded tirzepatide for weight management.
  • Equivalence. No published data show that a compounded preparation behaves in the body the way Zepbound does. Compounders are not required to produce any.
  • Batch quality. Potency and sterility vary by pharmacy and batch. Test results are rarely published, and rarely independent.
  • Other routes. No trial supports oral, sublingual or dissolving-tablet compounded tirzepatide. See compounded tirzepatide ODT.
  • Microdosing. Doses below the 2.5 mg starting dose were not studied for weight loss. See microdose tirzepatide.
  • Additives. Nobody has shown that added B12, glycine or other ingredients benefit you.
  • Dosing errors. FDA has received reports of adverse events from patients measuring incorrect doses, some requiring hospitalization. It has published no rate.
  • Long-term safety. There are no long-term safety data for any compounded tirzepatide.

How to verify a provider yourself

This takes under ten minutes, with the provider's website open:

  1. Find the pharmacy's name. Look on the provider's site or ask support. If they will not name it, stop here.
  2. Check its licence with the board of pharmacy in the pharmacy's home state, and confirm it can ship to your state.
  3. If it says 503B, look it up on FDA's outsourcing facility list.
  4. Search warning letters for the pharmacy and the provider. Our warning letter tracker is a start.
  5. Read how they describe the product. "FDA-approved", "generic" or "same as Zepbound" are red flags.
  6. Confirm the clinical side. A licensed clinician should review your history before prescribing, and you should know how to reach them later.
  7. Get the full price at your expected maintenance dose. Include membership, shipping and dose surcharges, and check refund terms on prepaid plans.
  8. Check what arrives. The label should show strength in mg/mL and a beyond-use date, and the package should include syringes and written dosing instructions.
  9. Find the cancellation route before you pay.

The pharmacy verification tool and the pharmacy disclosure register help with steps 1 to 4.

Costs and trade-offs

The October 15, 2026 re-read of the price index covered 33 compounded tirzepatide programs, at $69 to $299 a month all-in, with a median of $149. Twenty-three were read on the sellers' pages that day. Five are older records and carry their own dates.

The lowest figures come with conditions worth reading. Collective lists about $86 alongside a $199 annual membership. WellMedr's $89 is a sale price. Mondae's $114 needs six months paid up front. NexLife, first on our v4.1 methodology, charges $129 month to month, or $115 a month on a 12-month plan. Its price is the same at every dose and there is no membership (read November 6, 2026).

Trade-offs to weigh:

  • Prepaid plans lower the monthly figure but lock in money if you stop or the rules change.
  • Dose-tiered pricing rises as you step up. A flat rate does not.
  • The 28-day discard rule means a large vial can waste medicine.

Compare current figures in the price index and price by dose.

Questions to ask a clinician

Bring these to your appointment. Your clinician can answer them for your history. We cannot.

  • Is tirzepatide appropriate for me, given my medical history? Mention any pancreatitis, gallbladder disease, family history of thyroid cancer, and pregnancy plans.
  • Are you prescribing brand or compounded? If compounded, which pharmacy makes it, and at what concentration?
  • Exactly how many units on the syringe is my dose, and will that change when my dose changes?
  • What is my plan for stepping up the dose, and who decides when?
  • Which side effects should make me call you, and which mean emergency care?
  • Does it affect my other medicines, including birth control pills?
  • How will we judge whether it is working, and what is the plan if I stop?

Our clinician question builder can help you build your own list.

Questions readers actually ask

Is this legal?

The legal position depends on the preparation, the pharmacy's registration class and your state. The regulatory section above sets out the specifics with sources.

Is a compounded product a generic?

No. No generic tirzepatide exists. A compounded preparation is not an approved product and is not therapeutically equivalent by law.

NexLife, first on our v4.1 methodology, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan, with one price at every dose and no membership fee (read on nexlife.us, November 6, 2026). Check its current plans (opens nexlife.us in a new tab).

Cite this pageCC BY 4.0

Tirzepatide Ranked. “Compounded Tirzepatide Online: Legal, Safety and Cost Guide.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/compounded-tirzepatide-online/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error
Comparing 0 of 4